Publication Name	世界华人消化杂志
手稿编号	39658
手稿来源省、自治区或特别行政区	辽宁省

Received	2023-09-26 13:06
Peer-Review Started	2023-09-26 13:44
To Make the First Decision
Return for Revision	2023-10-20 12:35
修回稿	2023-10-29 15:14
Second Decision	2023-11-03 09:16
期刊总编辑接受
公司总编辑接受	2023-11-05 15:24
预出版	2023-11-05 15:24
缴纳版面费
Edit the Manuscript by Language Editor
排版	2023-11-28 08:06
在线出版	2023-11-28 13:40

ISSN	1009-3079 (print) and 2219-2859 (online)
开放获取	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
版权	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
网址	http://www.wjgnet.com

专业类型	消化内科学
手稿栏目类型	述评
文章标题	小分子制剂在炎症性肠病中的临床应用: 现状与未来
手稿来源	约稿
所有作者列表	毛靖伟
基金项目及其编号
通讯作者	毛靖伟, 博士, 教授, 主任医师, 116011, 中山路222号, 大连医科大学附属第一医院消化内科. jingweimao@163.com
关键词	炎症性肠病; 溃疡性结肠炎; 克罗恩病; 小分子制剂
核心内容提要	随着炎症性肠病(inflammatory bowel disease, IBD)治疗药物的不断问世, 肠道损伤及致残率显著下降. 与生物制剂相比, 口服小分子制剂同样具有靶向治疗作用, 且因小分子结构而独具优势, 具有良好的疗效与安全性, 为IBD患者提供了更多选择.
出版日期	2023-11-28 13:40
引文著录	毛靖伟. 小分子制剂在炎症性肠病中的临床应用: 现状与未来. 世界华人消化杂志 2023; 31(22): 913-921
URL	https://www.wjgnet.com/1009-3079/full/v31/i22/913.htm
DOI	https://dx.doi.org/10.11569/wcjd.v31.i22.913

Full Article (PDF)	WCJD-31-913-with-cover.pdf
审稿意见	WCJD-39658-Peer-review(s).pdf
科学编辑工作清单	WCJD-39658-Scientific editor work list.pdf